CBT vs CSTM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cabot Corporation presents a stable but stagnating profile, evidenced by a Piotroski F-Score of 4/9. While the company maintains strong profitability with an ROE of 21.82% and a consistent track record of earnings beats, it is currently facing significant headwinds with negative YoY revenue (-11.10%) and earnings growth (-18.20%). The stock is trading at a significant premium to both its Graham Number ($62.31) and Intrinsic Value ($40.04), suggesting limited upside potential at current price levels.
CSTM presents a dichotomy between explosive growth and deteriorating fundamental value. While the Piotroski F-Score of 4/9 indicates stable but mediocre financial health, the stock is trading at a significant premium to its Graham Number ($17.43) and Intrinsic Value ($13.44). Despite a very attractive PEG ratio of 0.40 and strong ROE of 32.39%, the combination of aggressive insider selling by the CEO and CFO and a high Debt/Equity ratio (2.12) suggests the current price may be overextended.
Compare Another Pair
Related Comparisons
CBT vs CSTM: Head-to-Head Comparison
This page compares Cabot Corporation (CBT) and Constellium SE (CSTM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.